Carfilzomib, bendamustine, dexamethasone in patients with advanced multiple myeloma: The EMN09 Phase I/II study of the European Myeloma Network

Martin Gramatzki,Massimo Offidani,Andreas Günther,Monika Engelhardt,Marco Salvini,Vittorio Montefusco,Francesca Patriarca,Emanuele Angelucci,Wolfram Poenisch,Stefano Spada,Natalie Schub,Silvia Gentili,Ralph Wäsch,Paolo Corradini,Hermann Einsele,Mario Boccadoro,Pieter Sonneveld,Francesca Gay

Clinical Lymphoma Myeloma and Leukemia（2019）

引用 0|浏览1

暂无评分

摘要

Despite recently introduced immunotherapeutic strategies the selection of an efficient, well-tolerated and affordable treatment option for advanced patients with relapsed/refractory multiple myeloma (RRMM) remains challenging. Since bendamustine (B) and the proteasome inhibitor carfilzomib (K) seem safe even in compromised patients and act synergistically a combination termed KBd including dexamethasone (d) was evaluated. This multicenter phase 1/2 trial was conducted within the European Myeloma Network as EMN09 study.

查看译文

关键词

advanced multiple myeloma,multiple myeloma,dexamethasone,carfilzomib,bendamustine

AI 理解论文

溯源树

样例

生成溯源树，研究论文发展脉络

Chat Paper

正在生成论文摘要